Adagene (ADAG) Competitors $2.22 +0.03 (+1.37%) Closing price 03:59 PM EasternExtended Trading$2.23 +0.01 (+0.27%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. CTMX, CGC, DMAC, OCGN, DSGN, RNAC, DRUG, NGNE, HUMA, and PBYIShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include CytomX Therapeutics (CTMX), Canopy Growth (CGC), DiaMedica Therapeutics (DMAC), Ocugen (OCGN), Design Therapeutics (DSGN), Cartesian Therapeutics (RNAC), Bright Minds Biosciences (DRUG), Neurogene (NGNE), Humacyte (HUMA), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors CytomX Therapeutics Canopy Growth DiaMedica Therapeutics Ocugen Design Therapeutics Cartesian Therapeutics Bright Minds Biosciences Neurogene Humacyte Puma Biotechnology Adagene (NASDAQ:ADAG) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Do insiders and institutionals believe in ADAG or CTMX? 9.5% of Adagene shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer ADAG or CTMX? Adagene presently has a consensus price target of $7.00, indicating a potential upside of 213.90%. CytomX Therapeutics has a consensus price target of $5.75, indicating a potential upside of 180.49%. Given Adagene's higher possible upside, equities analysts clearly believe Adagene is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ADAG or CTMX? Adagene has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Is ADAG or CTMX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Adagene's net margin of 0.00%. CytomX Therapeutics' return on equity of 158.70% beat Adagene's return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A CytomX Therapeutics 34.04%158.70%36.04% Does the media prefer ADAG or CTMX? In the previous week, Adagene and Adagene both had 2 articles in the media. CytomX Therapeutics' average media sentiment score of 1.88 beat Adagene's score of 0.92 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better valuation & earnings, ADAG or CTMX? CytomX Therapeutics has higher revenue and earnings than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K1,050.55-$33.42MN/AN/ACytomX Therapeutics$141.10M2.40$31.87M$0.563.66 SummaryCytomX Therapeutics beats Adagene on 9 of the 13 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.06M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.2231.3126.60Price / Sales1,050.55390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book2.798.0710.026.67Net Income-$33.42M-$54.08M$3.27B$265.59M7 Day Performance-2.19%2.26%3.17%3.42%1 Month Performance12.29%3.42%4.34%1.09%1 Year Performance-22.03%18.61%44.11%23.85% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene3.0138 of 5 stars$2.22+1.4%$7.00+215.3%-27.2%$104.58M$100K0.00260Gap UpCTMXCytomX Therapeutics4.3621 of 5 stars$2.12+11.0%$5.75+171.2%+73.9%$314.98M$141.10M3.79170Positive NewsHigh Trading VolumeCGCCanopy Growth0.2874 of 5 stars$1.37+5.4%N/A-72.9%$311.80M$225.65M-0.453,150Options VolumeDMACDiaMedica Therapeutics1.4922 of 5 stars$5.76-4.5%$12.33+114.1%+51.4%$311.68MN/A-8.3520Analyst UpgradeOCGNOcugen1.473 of 5 stars$1.04-1.0%$6.00+476.9%-21.8%$306.92M$4.05M-5.2080DSGNDesign Therapeutics0.2561 of 5 stars$5.40+1.3%N/A+7.5%$303.53MN/A-4.8240News CoverageRNACCartesian Therapeutics2.7097 of 5 stars$11.28-0.4%$40.00+254.6%-24.3%$294.60M$1.03M-0.2164Positive NewsDRUGBright Minds Biosciences2.4402 of 5 stars$45.55+8.9%$83.25+82.8%+3,483.5%$294.58MN/A-48.98N/ANGNENeurogene2.3705 of 5 stars$20.45-0.3%$46.17+125.8%-45.2%$292.72M$930K-4.7490News CoverageHUMAHumacyte2.1502 of 5 stars$1.80-4.3%$10.64+491.3%-77.0%$291.62M$1.57M-4.00150Analyst ForecastGap UpPBYIPuma Biotechnology4.1355 of 5 stars$5.01-12.6%$7.00+39.7%+100.8%$288.63M$238.06M5.11200Positive NewsHigh Trading Volume Related Companies and Tools Related Companies CTMX Competitors CGC Competitors DMAC Competitors OCGN Competitors DSGN Competitors RNAC Competitors DRUG Competitors NGNE Competitors HUMA Competitors PBYI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access